Dutogliptin Tartrate

Phase 3Small molecule

RRecardio, Inc.

Dutogliptin Tartrate is one of 39 small molecule programs targeting Myocardial Infarction. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myocardial InfarctionActive, not recruiting

Myocardial InfarctionPhase 3

Active, not recruiting

Competition

Competitive Landscape

232 competitors in Myocardial Infarction

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Phase 3

2 2

Medrol

Pfizer

Phase 3

2 3

Ikorel

Merck & Co.

Phase 3

2 4

Lovenox

Sanofi

Phase 3

1 5

Aranesp

Reopro

4 7

Zetia

OOrganon and Co

Phase 3

3 8

Jardiance

Boehringer Ingelheim

Phase 3

2 9

Aggrastat

MMedicure

Phase 3

1 10

Tekturna

Tibotec Pharmaceuticals, Ireland

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Myocardial Infarction2 trials

Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction

Unknown status·RRecardio, Inc.·Phase 3·NCT05881382·4,100 enrolled

Study of Dutogliptin in Combination With Filgrastim in Post-Myocardial Infarction

Completed·RRecardio, Inc.·Phase 2·NCT03486080·49 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Dutogliptin Tartrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dutogliptin Tartrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dutogliptin Tartrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Recardio, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRecardio, Inc.

Dutogliptin Tartrate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Myocardial Infarction2 trials

References

Drug Info

Quick Facts

Related News